Birmingham, ALNCT07228364Now EnrollingIRB Ready

Autosomal Dominant Polycystic Kidney Disease Clinical Trial in Birmingham, AL

Access cutting-edge autosomal dominant polycystic kidney disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access autosomal dominant polycystic kidney disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related autosomal dominant polycystic kidney disease treatment provided free

Apply for This Birmingham Location

Check if you qualify for this autosomal dominant polycystic kidney disease clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Autosomal Dominant Polycystic Kidney Disease Study in Birmingham

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes
eGFR = 45 to 90 mL/min /1.73m2
Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg/m2 (inclusive).
Females are to be of non-childbearing potential

Exclusion Criteria

As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study.
Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening.
History of QT prolongation associated with other medications that required discontinuation of that medication.
Congenital long QT syndrome.
History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation/flutter and controlled ventricular rate HR \< 100 bpm can be eligible as judged by the investigator.
Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.
Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.
Systolic BP \> 160 mmHg or diastolic BP \> 100mmHg or HR \< 50 bpm or \> 100 bpm at screening. Patients taking anti-hypertensive medication should be on a stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit.
Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.
Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT07228364) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Autosomal Dominant Polycystic Kidney Disease Treatment Options in Birmingham, AL

If you're searching for autosomal dominant polycystic kidney disease treatment options in Birmingham, AL, this clinical trial (NCT07228364) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced autosomal dominant polycystic kidney disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all autosomal dominant polycystic kidney disease clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Birmingham, AL

See all heart attack clinical trials recruiting in Birmingham — not just this study.

Browse Heart Attack Trials in Birmingham →

Browse More Trials by Condition

Heart Attack TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsPolycystic Kidney Disease TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL